The Australian New Zealand Clinical Trials Registry lists clinical trials including motor neurone disease (MND) studies in Australia and New Zealand, as well as trials from across the globe that have been completed, are currently recruiting or are pending.
Australian clinical trials
Copper-ATSM trial for MND to start in Australia in 2016
Read an overview of the copper-ATSM research
The first clinical trial of copper-ATSM as a potential treatment option for MND is expected to start in November 2016. Importantly, copper-ATSM therapy was developed in Australia. The sponsor is an Australian company Collaborative Medicinal Development.
that has been performed to date, the rationale for why this compound may be an effective treatment, and the status of the clinical trial.
Clinical trial of antiretroviral therapy starting in October Australia in 2016
The Lighthouse Project: A Phase 2 clinical trial of antiretroviral therapy for amyotrophic lateral sclerosis
Professor Julian Gold, The Albion Centre, Sydney
The Lighthouse Project will take place at four sites in Australia. The overall aim of the study is to test the possibility that a virus may be a cause or trigger for motor neurone disease. For more information.
Australian Clinical Trials – is the NHMRC's database of clinical trials currently being conducted in Australia. The Australian Clinical Trials site also lists other trial websites which may include trials not registered with the NHMRC.
Australian New Zealand Clinical Trials Registry – is an online clinical trials registry for Australia and New Zealand.
To read MND Australia's Position Statement on development and approval of drugs to treat motor neurone disease click here.
International clinical trials
International Clinical Trials Registry Platform – is the World Health Organization's search portal for clinical trials. The clinical trials listed in the database are collected from a range of sources, including the Australian New Zealand Clinical Trials Registry listed above.
ClinicalTrials.gov – is U.S. National Institutes of Health's database of private and public clinical trials conducted in the U.S. and elsewhere around the world.
An EphA4 inhibitor as a potential biotherapeutic to treat MND
Following an announcement by Queensland Premier Annastacia Palaszczuk in June 2016, Brisbane-based Patheon Biologics is manufacturing a protein, which will undergo laboratory testing to see if it is suitable for MND clinical trials. A Queensland research team, led by Professor Perry Bartlett from the Queensland Brain Institute, and Professor Andrew Boyd, from the QIMR Berghofer Medical Research Institute, has found a protein called EphA4 plays a role in repairing damaged motor neurones. EphA4 appears to impede the recovery of motor neurones following injury, which has led to research to develop an EphA4 inhibitor, which could be effective in treating MND in humans. Preclinical research is underway to better understand the inhibitor before a first-in-human study can begin.